SP
ALNY icon

Steelhead Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Steelhead Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,600
Closed -$721K – 42
2022
Q3 		$721K Buy
+3,600
New +$687K 0.05% 42

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Steelhead Partners's ALNY Position: Q4 2022 in Review

Steelhead Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 3,600 shares — an estimated $721K sold.

Steelhead Partners first reported a position in ALNY in Q3 2022 and held it in 1 quarter. The position peaked at $721K in Q3 2022. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

  • Steelhead Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Steelhead Partners sold 3,600 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $721K.
  • Steelhead Partners first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Steelhead Partners's Alnylam Pharmaceuticals position peaked at $721K in Q3 2022.
  • 487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Steelhead Partners's 13F filing for Q4 2022, filed 14 Feb 2023.